Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vvax 001

Next Previous
Drug Profile

Vvax 001

Alternative Names: rSFVeE6,7; Semliki Forest Virus Based Cancer Vaccine; SFVeE6,7; Vvax-001

Latest Information Update: 30 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViciniVax
  • Developer University of Groningen
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Human papillomavirus E6 protein inhibitors; Human papillomavirus E7 protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cervical intraepithelial neoplasia

Most Recent Events

  • 30 Nov 2022 Vvax 001 is still in phase II trials for Cervical intraepithelial neoplasia in Netherlands (IM) (EudraCT2019-004050-29)
  • 30 Mar 2020 Phase-II clinical trials in Cervical intraepithelial neoplasia in Netherlands (IM) (EudraCT2019-004050-29)
  • 28 Feb 2020 No recent reports of development identified for phase-I development in Cervical-intraepithelial-neoplasia in Netherlands (IM, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top